Integrated BioTherapeutics.
作者信息
Aman M Javad
机构信息
a Integrated BioTherapeutics, Inc. , Rockville , Maryland , USA.
出版信息
Hum Vaccin Immunother. 2018 Jun 3;14(6):1308-1310. doi: 10.1080/21645515.2018.1440105. Epub 2018 Apr 11.
Abstract
摘要
相似文献
1
Integrated BioTherapeutics.整合生物治疗公司
Hum Vaccin Immunother. 2018 Jun 3;14(6):1308-1310. doi: 10.1080/21645515.2018.1440105. Epub 2018 Apr 11.
2
Letter from the editor.编辑来信。
Hum Vaccin Immunother. 2012 Mar;8(3):281. doi: 10.4161/hv.19911. Epub 2012 Mar 1.
3
Known unknowns and unknown unknowns.已知的未知与未知的未知。
Lancet Infect Dis. 2018 Apr;18(4):385-386. doi: 10.1016/S1473-3099(18)30181-6. Epub 2018 Mar 21.
4
Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?按需生产疫苗：应对新出现病原体和生物防御的潜在解决方案？
Hum Vaccin Immunother. 2013 Sep;9(9):1877-84. doi: 10.4161/hv.25611. Epub 2013 Jul 22.
5
Vaccinology in the 21st century-The 10th Annual Vaccine Congress.21世纪的疫苗学——第十届年度疫苗大会
Vaccine. 2017 Aug 16;35(35 Pt A):4451-4452. doi: 10.1016/j.vaccine.2017.07.015. Epub 2017 Jul 15.
6
Second coming: the re-emergence and modernization of immunotherapy by vaccines as a component of leprosy control.再度兴起：作为麻风病控制组成部分的疫苗免疫疗法的重新出现与现代化
Future Microbiol. 2018 Oct;13:1449-1451. doi: 10.2217/fmb-2018-0186. Epub 2018 Oct 12.
7
Monoclonal Antibodies for Emerging Infectious Diseases - Borrowing from History.用于新发传染病的单克隆抗体——借鉴历史
N Engl J Med. 2018 Apr 19;378(16):1469-1472. doi: 10.1056/NEJMp1802256. Epub 2018 Mar 7.
8
Vaccines We Need But Don't Have.我们需要但尚未拥有的疫苗。
Viral Immunol. 2018 Mar;31(2):114-116. doi: 10.1089/vim.2017.0126. Epub 2017 Nov 13.
9
Self-disseminating vaccines for emerging infectious diseases.用于新发传染病的自我传播疫苗。
Expert Rev Vaccines. 2016;15(1):31-9. doi: 10.1586/14760584.2016.1106942. Epub 2015 Nov 2.
10
The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.系统生物学方法在确定更有效的疫苗的分子特征方面的作用。
Expert Rev Vaccines. 2019 Mar;18(3):253-267. doi: 10.1080/14760584.2019.1575208. Epub 2019 Feb 11.
引用本文的文献
1
A promising vaccine adjuvant candidate to overcome infection based on innate immunity.一种基于先天免疫来克服感染的有前景的疫苗佐剂候选物。
Clin Exp Vaccine Res. 2025 Jul;14(3):189-202. doi: 10.7774/cevr.2025.14.e27. Epub 2025 Jun 13.
2
in Inflammation and Pain: Update on Pathologic Mechanisms.《炎症与疼痛：病理机制的最新进展》
Pathogens. 2025 Feb 12;14(2):185. doi: 10.3390/pathogens14020185.
3
Biofilm Producing Methicillin-Resistant (MRSA) Infections in Humans: Clinical Implications and Management.人类中产生生物膜的耐甲氧西林金黄色葡萄球菌（MRSA）感染：临床意义与管理
Pathogens. 2024 Jan 15;13(1):76. doi: 10.3390/pathogens13010076.
4
Integrating complex host-pathogen immune environments into S. aureus vaccine studies.将复杂的宿主-病原体免疫环境纳入金黄色葡萄球菌疫苗研究。
Cell Chem Biol. 2022 May 19;29(5):730-740. doi: 10.1016/j.chembiol.2022.04.003.
5
Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies.疫苗研发：过去、现在和未来，包括新的治疗策略。
Front Immunol. 2021 Jul 7;12:705360. doi: 10.3389/fimmu.2021.705360. eCollection 2021.
6
T Cell Immunity and the Quest for Protective Vaccines against Infection.T细胞免疫与寻求抗感染保护性疫苗
Microorganisms. 2020 Dec 6;8(12):1936. doi: 10.3390/microorganisms8121936.
7
Iron Metabolism at the Interface between Host and Pathogen: From Nutritional Immunity to Antibacterial Development.宿主与病原体之间的铁代谢：从营养免疫到抗菌发展。
Int J Mol Sci. 2020 Mar 20;21(6):2145. doi: 10.3390/ijms21062145.
8
Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms.开发针对金黄色葡萄球菌侵袭性感染的疫苗：基于人体免疫、遗传学和细菌逃避机制的证据。
FEMS Microbiol Rev. 2020 Jan 1;44(1):123-153. doi: 10.1093/femsre/fuz030.
本文引用的文献
1
Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.免疫引发的广泛保护性抗体揭示埃博拉病毒融合环为易损位点。
Cell. 2017 May 18;169(5):891-904.e15. doi: 10.1016/j.cell.2017.04.038.
2
Protective efficacy of a novel alpha hemolysin subunit vaccine (AT62) against Staphylococcus aureus skin and soft tissue infections.新型α溶血素亚单位疫苗（AT62）对金黄色葡萄球菌皮肤和软组织感染的保护效力
Vaccine. 2016 Dec 7;34(50):6402-6407. doi: 10.1016/j.vaccine.2016.09.061. Epub 2016 Nov 12.
3
Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax.一种经肠胃外给药的、基于结构合理修饰的重组葡萄球菌肠毒素B蛋白疫苗STEBVax的安全性和免疫原性。
Clin Vaccine Immunol. 2016 Dec 5;23(12):918-925. doi: 10.1128/CVI.00399-16. Print 2016 Dec.
4
Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.通过糖蛋白受体结合位点内独特暴露的表位对埃博拉病毒和苏丹病毒感染进行抗体治疗。
Cell Rep. 2016 May 17;15(7):1514-1526. doi: 10.1016/j.celrep.2016.04.026. Epub 2016 May 5.
5
Structurally designed attenuated subunit vaccines for S. aureus LukS-PV and LukF-PV confer protection in a mouse bacteremia model.结构设计的金黄色葡萄球菌 LukS-PV 和 LukF-PV 减毒亚单位疫苗在小鼠菌血症模型中提供保护。
PLoS One. 2013 Jun 7;8(6):e65384. doi: 10.1371/journal.pone.0065384. Print 2013.
6
Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections.金黄色葡萄球菌外毒素抗体水平较低与住院的金黄色葡萄球菌侵袭性感染成年人脓毒症有关。
J Infect Dis. 2012 Sep 15;206(6):915-23. doi: 10.1093/infdis/jis462. Epub 2012 Jul 17.
7
Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia.新型结构设计的金黄色葡萄球菌α-溶血素疫苗：预防菌血症和肺炎。
PLoS One. 2012;7(6):e38567. doi: 10.1371/journal.pone.0038567. Epub 2012 Jun 6.
Zotero 插件